Watchlist Price Alert

Catalyst Pharmaceuticals ... (CPRX)

NASDAQ: CPRX · Real-Time Price · USD

23.36

0.60 (2.64%)

At close: May 09, 2025, 3:59 PM

22.98

-1.61%

After-hours: May 09, 2025, 05:57 PM EDT

2.64% (1D)

Bid	21.96
Market Cap	2.85B
Revenue (ttm)	491.73M
Net Income (ttm)	163.89M
EPS (ttm)	1.31
PE Ratio (ttm)	17.83
Forward PE	13.96
Analyst	Buy

Ask	24
Volume	1,329,367
Avg. Volume (20D)	1,257,570
Open	23.10
Previous Close	22.76
Day's Range	22.89 - 23.70
52-Week Range	14.47 - 26.16
Beta	0.70

About CPRX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CPRX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CPRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Catalyst Pharmaceuticals has released their quartely earnings on May 7, 2025:

Revenue of $141.42M exceeds estimates by $10.56M, with 43.56% YoY growth.

EPS of 0.68 exceeds estimates by 0.15, with 78.95% YoY growth.

Why Price Moved

1 day ago New

-2.98%

Catalyst Pharmaceuticals shares are trading lower ... Unlock content with Pro Subscription

1 month ago

-1.88%

Catalyst Pharmaceuticals shares are trading higher after the company announced that Health Canada accepted its AGAMREE new drug submission with priority review.

News

1 day ago · seekingalpha.com

Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2025 Earnings Call Transcript

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Michael Kalb - Executive Vice President & Chief Financial Officer Richard Dal...

1 day ago · zacks.com

Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y

CPRX reports strong first-quarter 2025 results, beating earnings and revenue estimates, primarily driven by Firdapse sales.

2 days ago · zacks.com

Compared to Estimates, Catalyst (CPRX) Q1 Earnings: A Look at Key Metrics

The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimat...

2 days ago · zacks.com

Catalyst Pharmaceutical (CPRX) Q1 Earnings and Revenues Top Estimates

Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.38 per share a year ago.

1 week ago · zacks.com

Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: Should You Buy?

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago · fool.com

Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday

As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the stock market on Thursday. It had one of its worst tradin...

1 month ago · zacks.com

Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

1 month ago · investors.com

Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win

This IBD 50 holding holds top notch ratings amid a market downturn. The post Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win appeared first on Investor's Business Daily.

1 month ago · fxempire.com

Strong Revenue, Drug Performance Lift Catalyst Shares

Big Money continues buying Catalyst Pharmaceuticals, Inc. (CPRX).

1 month ago · zacks.com

Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains?

Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in t...

Load More News